Advanced search
Publication Cover
Cancer Management and Research Volume 12, 2020 - Issue
Submit an article Journal homepage
109
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor

Jian-De Cheng1 Department of Respiratory and Critical Care Medicine, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China
,
Li-Xun Chai2 Department of Thoracic Surgery, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China
,
Zhi-Ping Zhao1 Department of Respiratory and Critical Care Medicine, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China
,
Yan-Yan Hao1 Department of Respiratory and Critical Care Medicine, The Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, People’s Republic of China
&
Shuo Li3 Department of Respiratory and Critical Medicine, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of ChinaCorrespondence[email protected]
Pages 5641-5650 | Published online: 12 Jul 2020

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Wen-Xia Hu, Jing-Cui Peng, Yun Wang, Hao Jin & Nan Geng. (2022) Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study. International Journal of General Medicine 15, pages 4453-4464.
Read now
Song Zhang, Xin Wang, Hao Gu & Jun-Qi Liu. (2022) Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study. Cancer Management and Research 14, pages 1715-1727.
Read now
Hong-Tao Jiang, Wei Li, Biao Zhang, Qiang Gong & Hai-Ling Qie. (2021) Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study. International Journal of General Medicine 14, pages 7625-7637.
Read now
Rui-Tao Wang, Yang Zhao, An-Lei Wang, Yu-Ting Wang, Zhong-Ping Yin & Kai Chen. (2021) Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study. International Journal of General Medicine 14, pages 5363-5373.
Read now

Articles from other publishers (10)

Shu Zhao, Peng Wang, Fan Yin, Junjie Wu, Yuying Wang, Peng Li, Yong Zhang, Jing Yang, Xueguang Guo, Dong Zhang & Peng Song. (2022) Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib. Tumori Journal 109:2, pages 186-196.
Crossref
Fengwu Chen, Huarong Peng, Haiyun Liu & Liming Peng. (2022) Factors Influencing the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer. International Journal of Pharmacology 18:5, pages 1071-1078.
Crossref
Bin Zhou, Qiang Gong, Ben Li, Hai‐Ling Qie, Wei Li, Hong‐Tao Jiang & He‐Fei Li. (2022) Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study. Journal of Clinical Pharmacy and Therapeutics 47:5, pages 643-651.
Crossref
Li-Hua Li, Wen-Chao Chen & Gang Wu. (2022) Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. Disease Markers 2022, pages 1-10.
Crossref
Tian Chen, Gaofeng Liang, Zhenfei Xiang, Jinxian He, Xiaoyu Xu & Mengqiu Tang. (2022) Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy. Journal of Clinical Laboratory Analysis 36:4.
Crossref
Bing Lv, Jing Chen & Xiao-Liang Liu. (2022) Anlotinib-Induced Hypertension: Current Concepts and Future Prospects. Current Pharmaceutical Design 28:3, pages 216-224.
Crossref
Xiaoyuan Li, Yang Cheng, Baorang Zhu, Ming Geng, Peng Yan & Mu Hu. (2022) Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study . Technology in Cancer Research & Treatment 21, pages 153303382210809.
Crossref
Jiaojiao Suo, Yu Sun, Yan Fu, Weigang Xiu, Xuanwei Zhang, Yan Wang & Jiang Zhu. (2021) A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy. Frontiers in Oncology 11.
Crossref
Mengqiu Tang, Chao Song, Yaowen Zhang, Xiaoyu Xu, Chen Wang, Zhanchun Zhang & Tian Chen. (2021) Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib. Lipids in Health and Disease 20:1.
Crossref
Yanjun Su, Shaohao Cheng, Jun Qian, Min Zhang, Tuanli Li, Ying Zhang, Chang Diao, Ling Zhang & Ruochuan Cheng. (2021) Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations. Frontiers in Oncology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.